托西利祖马布在患有系统性硬化症相关的间歇性肺部疾病的患者中:系统性审查和元分析
Marya Ghazipura1,2,3, Madalina Macrea4,5, Derrick Herman6
1ZS Associates, Global Health Economics and Outcomes Research, New York, New York.
Annals of the American Thoracic Society
|September 29, 2023
概括
与安慰剂相比,托西利祖马布在治疗系统性硬化症相关的间歇性肺病 (SSc-ILD) 中显示出前景,减缓疾病进展和减少不良事件. 然而,非常低质量的证据需要进一步的大规模研究.
科学领域:
- 肺部病理学 肺部病理学
- 类风湿病学 类风湿病学
- 临床药理学 临床药理学
背景情况:
- 系统性硬化症相关的间歇性肺病 (SSc-ILD) 是一种需要有效治疗策略的重大并发症.
- 美国胸腔学会 (ATS) 为SSc-ILD制定了临床实践指南,强调需要基于证据的治疗选择.
- 托西利祖马布是一种干白素-6受体抑制剂,其有效性在SSc-ILD中得到了研究.
结论:
- 在SSc-ILD中使用托西利祖马布与疾病进展的减少以及比安慰剂更好的毒性概况有关.
- 尽管有积极的趋势,但证据的整体质量非常低.
- 专门为SSc-ILD中托西利祖马布设计的大型前性研究对于证实这些发现和指导临床实践至关重要.
相关概念视频
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.5K
COPD: Management Using Bronchodilators and Corticosteroids
236
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
236
Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K
Antiasthma Drugs: Leukotriene Modifiers
338
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
338
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K


